Since the successful treatment of lung cancer with the first generation of EGFR inhibitors, a new chapter in targeted therapy for lung cancer has been opened, and targeted therapy has led to improved survival rates for many patients with intermediate to advanced NSCLC [13, 14]. This evidence concerns the gene EGFR and lung cancer.